AHNAK-modified microbubbles for the intracranial delivery of triptolide: In-vitro and in-vivo investigations.
Authors: Feng Y, An R, Zhang Y, Chen M, Wang L, Duan Y, Xing C
Autophagic dysfunction related cascade events might induce the accumulation of α-synuclein (αSyn) in Parkinson's disease (PD). Triptolide (T<sub>10</sub>) has been reported as a potential autophagy inducer but limited by hepatotoxicity, low solubility and rapid metabolism. In this study, a novel AHNAK-targeted microbubbles integrated with T<sub>10</sub> (T<sub>10</sub>-AHNAK-MBs) was developed to alleviate motor deficit in rAAV2/5-wild type and A53T mutant αSyn transfected PD mouse model. AHNAK facilitated the accumulation of microbubbles (MBs) near the cerebral vessel wall. Furthermore, bubble cavitation caused by focused-ultrasound (FUS) exposure could simultaneously induce drug release and blood-brain-barrier opening in the area of interest. The results of western blotting, thioflavin S staining, immunofluorescence, ELISA and behavior test demonstrated that T<sub>10</sub>-AHNAK-MBs with FUS exposure (T<sub>10</sub>-AHNAK-MBs-FUS) could significantly delivery more T<sub>10</sub> into substantia nigra, promote clearance of various forms of αSyn, reduce tyrosine hydroxylase positive neuron loss, restore dopamine secretion, and eventually alleviate motor deficits, along with largely reduced adverse effects. The analyses of autophagic markers suggested that autophagy lysosome pathway (ALP) might dominate the T<sub>10</sub>-induced αSyn degeneration, including the oligomers and pre-formed fibrils. Thus, T<sub>10</sub>-AHNAK-MBs-FUS constitutes a promising strategy against the motor deficits in PD by promoting clearance of pathogenic αSyn aggregates via inducing ALP.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To evaluate AHNAK-modified microbubbles as a delivery system for intracranial administration of triptolide through in vitro and in vivo studies.
Cargo name and characteristics
Triptolide (small-molecule diterpenoid natural product with anti-inflammatory and anticancer properties)
Route of administration
intracranial
Outcomes and Safety
Summary of Outcomes
The provided document contains only the paper title and no experimental results, so the main biological or behavioral effects cannot be determined; no focused ultrasound parameters or successful settings are reported in the provided text.
Safety-related matter
The provided text (title only) contains no information regarding safety or adverse effects; no adverse effects are mentioned.
Brain Region
Ultrasound Parameters
Focal Characteristics
Focal depth: None; Focal length: None; Aperture size: None
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search